bignose pom16 Dec 2017 13:11
good posts. with regard to increasing batch size , are they basically trying to get more doses per can and then sell can at a lower price per dose ? why the need for this anyway?
found this on some chinese news website and translated it.
Ming Pao News】 Regent Pacific (0575) In recent years, the transformation of investment in life medicine, the first gun project to treat male premature ejaculation topical spray Fortacin first launched in the UK market. Michael Wylie, chief scientific officer of the group, plans to launch the product next year in Europe and expects the United States to have a bigger market, believing it will have greater commercial value in two to three years. The group also plans to apply to the medical institutions in Hong Kong to enter the market and is expected to finalize it by the end of next year.
British rule premature ejaculation spray doctors have started a prescription
Wylie said that as Fortacin conducted clinical tests already known to local physicians in the UK market, the local physicians started prescribing when the product was recently introduced locally. He added Regent's Recordati assistance in understanding the urological market helped open the European market and estimated that the product will land on the European market in March and April next year. However, compared to the surface of the European market, the actual decentralized operation and to make different pricing, the US market can unify the price of the product launch, the market size up to 6-7 times in Europe, and can be 12 doses per can in Europe compared to each tank 20 dose sales, the U.S. market is expected to become their main market in the future.
In his opinion, Fortacin is expected to take a share of the non-bleeding needs of the Viagra and Cialis who share Bacheng compared to other products that require premature ejaculation.
It is proposed to register with Hong Kong Department of Health
After the group moved from the UK to Hong Kong, Wylie believes it will be more tax efficient and plans to apply for registration and registration with the Department of Health in Hong Kong. If all goes well, it is hoped to open the Hong Kong market by the end of next year. In the Asia Pacific region, the group believes its products can secure development opportunities in Australia and South Korea.